IMV Inc IMVIF

RE:RE:RE:RE:RE:Hmm. So, collaboration continues?

[qwerty22]

Accelerated approval is (almost) always the case in cancer in these types of studies because it depends on surrogate endpoints, you shouldn't think this is some sort of special achievement by IMV.  This is not a registrational trial although it might expand into one so you're going to have to define what you mean by jackpot, this is probably the most disappointing aspect of the announcement for me that we aren't a whole lot closer to the registrational trial.

Biotech010 wrote:

the trial is designed to get the accelarated approval. They need to repeat in a larger number of patients the data that they had in the PDL-1 positive patient population. 

That is want they wanted to hear fromt the FDA and that's what they got. So if in Q1 2022 the interim results point to the same results.... jackpot. 

For now, it's a waiting game. I expect Fred and his team to prep up investors confidence with some stunning COVID results / launch of phase 1/2 soon.